Beta-blockers are cardiovascular and neurologic drugs that reduce the effects of sympathetic stimulation on beta-adrenergic receptors. This cheat sheet helps college students connect receptor pharmacology to clinical indications, safety risks, and monitoring priorities. It is useful for reviewing mechanisms, comparing selective and nonselective agents, and recognizing high-risk prescribing situations.
The most important concept is that beta-1 blockade mainly decreases heart rate, contractility, renin release, and myocardial oxygen demand. Beta-2 blockade can cause bronchoconstriction and alter glucose recovery, which matters in asthma, COPD, and diabetes. Drug choice depends on receptor selectivity, added alpha-1 blockade, lipid solubility, route, indication, and patient comorbidities.
Key Facts
- Beta-1 receptor blockade decreases heart rate, AV node conduction, myocardial contractility, renin release, and myocardial oxygen demand.
- Beta-2 receptor blockade can cause bronchoconstriction and may reduce glycogenolysis and glucagon release during hypoglycemia.
- Cardioselective beta-blockers, such as metoprolol, atenolol, bisoprolol, and esmolol, preferentially block beta-1 receptors at usual doses.
- Nonselective beta-blockers, such as propranolol, nadolol, and timolol, block both beta-1 and beta-2 receptors.
- Mixed alpha-1 and beta blockers, such as carvedilol and labetalol, lower blood pressure by reducing heart rate and decreasing peripheral vascular resistance.
- Abrupt beta-blocker withdrawal can cause rebound tachycardia, hypertension, angina, or myocardial infarction, so long-term therapy is usually tapered.
- Major adverse effects include bradycardia, hypotension, fatigue, dizziness, AV block, bronchospasm, sexual dysfunction, and masking of hypoglycemia symptoms.
- Beta-blockers are used for hypertension, angina, heart failure with reduced ejection fraction, post-myocardial infarction care, rate control, migraine prevention, essential tremor, glaucoma, and thyrotoxicosis symptom control.
Vocabulary
- Beta-blocker
- A drug that blocks beta-adrenergic receptors and reduces the physiologic effects of epinephrine and norepinephrine.
- Cardioselective
- A property of some beta-blockers that means they preferentially block beta-1 receptors in the heart at typical therapeutic doses.
- Nonselective beta-blocker
- A beta-blocker that inhibits both beta-1 and beta-2 receptors, increasing the risk of bronchospasm in susceptible patients.
- Intrinsic sympathomimetic activity
- Partial agonist activity in some beta-blockers that produces mild receptor stimulation while still blocking stronger catecholamine effects.
- AV node
- The atrioventricular node is cardiac conduction tissue that slows electrical signals between the atria and ventricles.
- Rebound effect
- A worsening of sympathetic symptoms, such as tachycardia or hypertension, that can occur after sudden beta-blocker discontinuation.
Common Mistakes to Avoid
- Assuming all beta-blockers are interchangeable is wrong because receptor selectivity, half-life, lipid solubility, and approved indications differ between agents.
- Using a nonselective beta-blocker in uncontrolled asthma is risky because beta-2 blockade can trigger bronchoconstriction and worsen breathing.
- Stopping chronic beta-blocker therapy suddenly is unsafe because receptor upregulation can lead to rebound tachycardia, hypertension, angina, or infarction.
- Ignoring heart rate and blood pressure before dosing is wrong because beta-blockers can worsen bradycardia, hypotension, and conduction block.
- Assuming beta-blockers are always contraindicated in diabetes is too simplistic because they can be used when indicated, but patients need counseling about masked hypoglycemia symptoms.
Practice Questions
- 1 A patient has a resting heart rate of 48 beats/min and is scheduled for a beta-blocker dose. What safety concern should be assessed before administration?
- 2 A drug reduces heart rate from 96 beats/min to 72 beats/min. What is the percent decrease in heart rate?
- 3 A patient with asthma needs migraine prevention. Which is generally safer to consider: a cardioselective beta-1 blocker or a nonselective beta-blocker, and why?
- 4 Why can the same beta-blocker mechanism be helpful after myocardial infarction but risky in a patient with severe bradycardia?